Fig. 2: E-regulated UcPS is dependent on TMED10.

a Immunofluorescence of U2OS expressing GFP-ERGIC53 and Myc-tagged E of indicated coronaviruses. b Immunofluorescence of U2OS expressing GFP-ERGIC53, TMED10-V5 and Myc-E-SARS2. c mIL1β-HA secretion in WT and TMED10-KO HEK293T cells transfected with mIL1β-HA alone or together expressed with or without Myc-E-SARS2. d mIL1β secretion in WT and TMED10-KO THP-1 cells expressed with or without Myc-E-SARS2, TMED10-V5 or both as indicated. e mIL33 secretion in WT or TMED10-KO BEAS-2B cells in the absence or presence of Myc-E-SARS2 or TMED10-V5 expression. f–i WT and TMED10KO mice injected with AAV-GFP or AAV-Myc-E-SARS2 were challenged with 15 mg/kg LPS for 15 h and euthanized. Expression of Myc-E-SARS2 or GFP in the lung was verified by IF (h, upper panel). Serum IL1β levels were determined by ELISA in (f). IL6 mRNA levels in indicated tissues were analyzed in (g). Lung inflammation was analyzed by H&E staining (h, middle and lower panel) and inflammatory area was quantified in (i). j Co-IP using HEK293T cells with Myc-E-SARS2 and TMED10-V5 or TMED10∆CT-V5. k GST pull down analysis using GST, GST-TMED10, and MBP-Myc-E of SARS2 proteins. l Pull-down analysis using MBP-Myc-E of SARS2 protein and Ctrl, TMED6-CT or TMED10-CT peptides. m mIL1β secretion in TMED10-KO THP-1 cells transfected with or without Myc-E-SARS2 in the presence of TMED10-WT or TMED10∆CT mutant. n Co-IP using HEK293T cells with TMED10-V5 and Myc-tagged E of indicated coronaviruses. o Crosslink assay performed using HEK293T cells expressing TMED10-V5 in the absence or presence of Myc-tagged E of indicated coronaviruses. WT, Wild type; 10KO, TMED10-KO; 10V5, TMED10-V5; TM10, TMED10; TM6, TMED6; DSS, disuccinimidyl suberate. Data are mean ± s.d. Statistical significance was assessed using one-way ANOVA (n = 5) followed by Tukey’s multiple-comparison test. P values are indicated. Scale bars, 10 μm (a, b) and 50 μm (k). Source data are provided as a Source Data file.